Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04181775 · ClinicalTrials.gov registry record
Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 471
- Enrollment target
NCT04181775: Completed study, sponsored by Methodist Health System.
NCT04181775 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 471 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04181775 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 471 participants
- Enrollment target
Study Summary
The rationale for this study is to evaluate the effectiveness of a risk prediction tool for patients who are at high risk for ADEs resulting in hospitalization or ED revisit. The ADE-RED score initiates a PLMR that literature has shown reduces medication discrepancies and ADEs at hospital admission and discharge. No current system identifies patients presenting to the ED that may benefit from PMLR independent of an admission disposition. The ADE-RED scoring tool will reduce the incidence of future visits to the ED or future admissions by identifying patients who are at high risk for ADE-related readmissions.
Primary Outcome
Incidences of ADE-related readmission within 30 days of prior ED visit.
Interventions
- DIAGNOSTIC_TEST ADE-RED scoring tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2019-11-08 |
| Est. Completion | 2020-06-22 |
What the finished NCT04181775 record still lists
NCT04181775 is an observational study that tracks outcomes without assigning an intervention. The registered 471 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ADE-RED scoring tool is the first listed.
NCT04181775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04181775 about?
NCT04181775 is a clinical study titled "Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)". The rationale for this study is to evaluate the effectiveness of a risk prediction tool for patients who are at high risk for ADEs resulting in hospitalization or ED revisit. The ADE-RED score initiates a PLMR that literature has shown reduces medication discrepancies and ADEs at hospital admission ...
What is the current status of trial NCT04181775?
This trial is currently completed. The enrollment target is 471 participants. The study started on 2019-11-08. Estimated completion is 2020-06-22.
What interventions are being tested in trial NCT04181775?
The interventions under investigation include: ADE-RED scoring tool (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04181775?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03010150 · 471 participants
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
- NCT05201404 · 471 participants · Phase 3
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- NCT06947187 · 472 participants · NA
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI